Lygos uses its proprietary fermentation and synthetic bioengineering process to produce any common, rare, or novel cannabinoid and cannabinoid-based product of interest in an environmentally safe, sustainable, and cost-effective manner. This is accomplished by modifying baker’s yeast (Saccharomyces cerevisiae) to produce compounds in the same way that the cannabis plant does. By controlling this process at the molecular level, we can obtain highly efficient production of cannabinoids. Since no plants are used in the process we do not require large amounts of land, water, energy, fertilizers, or pesticides.

Lygos’ process can be scaled to deliver cannabinoids that can meet large scale commercial needs, starting with supply of 10s to 100s of kilograms.

Lygos provides ultra-high purity cannabinoids that are free from contamination of other cannabinoids, terpenes or other plant compounds. They also adhere to ICH guidelines or other specifications provided by our customers. Cannabinoids produced from agricultural production occur simultaneously and are structurally similar to each other, making the separation of these compounds difficult at scale. As a result, the impurity profiles of cannabinoids that are isolated from the plant often contain other cannabinoids. Lygos carefully controls the production of only a single cannabinoid, enabling high purity production of cannabinoids >99%, as well as a consistent impurity profile that is void of active cannabinoids or other compounds.

Lygos uses its proprietary fermentation and synthetic bioengineering process in a repeatable and scalable manner. In leveraging this process, our products exhibit highly reproducible profiles that maintain consistent odorless and colorless results. Further, the high performance platform can meet many common or unique specification profiles to match a range of potential needs.

Lygos’ production platform is similar to other biosynthetic production platforms that have been used to produce active pharmaceutical ingredients (APIs) in the pharmaceutical industry. The highly controlled process can be implemented so that it conforms with GMP or FDA guidelines.

The cannabinoids produced from Lygos’ platform can be mixed into various formulations in the same way as plant derived cannabinoids. Lygos can also help with formulating and mixing, and on demand, we can deliver oil based, aqueous salt, ester forms or other related phases of interest to aid in formulation requirements.